Long‐term immune response accompanies clinical outcomes in severe asthmatics treated with <scp>anti‐IL</scp>‐5/<scp>IL‐5R</scp> biologics-Reference-Cited by-同舟云学术

Long‐term immune response accompanies clinical outcomes in severe asthmatics treated with anti‐IL‐5/IL‐5R biologics

Published:2023-08-29 Issue:11 Volume:78 Page:3027-3031
ISSN:0105-4538
Container-title:Allergy
language:en
Short-container-title:Allergy

Author:

Lorente‐Sorolla C.¹^ORCID,Bernaola J.²,Sánchez‐Mellado D.³,Gil‐Martínez M.¹⁴^ORCID,Naharro‐González S.¹^ORCID,Betancor D.²^ORCID,Fernández‐Nieto M.²,Pinillos‐Robles E. J.³^ORCID,Santillán Coello J. M.⁵,Villacampa‐Aubá J. M.⁵^ORCID,Rodríguez‐Nieto M. J.³^ORCID,Sastre J.²⁴^ORCID,Valverde‐Monge M.²⁴^ORCID,Rodrigo‐Muñoz J. M.¹⁴^ORCID,del Pozo V.¹⁴⁶^ORCID

Affiliation:

1. Immunoallergy Laboratory, Department of Immunology Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS‐FJD, UAM) Madrid Spain

2. Allergy Unit Hospital Universitario Fundación Jiménez Díaz Madrid Spain

3. Pulmonology Unit Hospital Universitario Fundación Jiménez Díaz Madrid Spain

4. CIBER de Enfermedades Respiratorias (CIBERES) Instituto de Salud Carlos III (ISCIII) Madrid Spain

5. Department of ENT and Cervicofacial Surgery Fundación Jiménez Díaz University Hospital Madrid Spain

6. Universidad Autónoma de Madrid Madrid Spain

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/all.15872

Reference11 articles.

1. A pragmatic guide to choosing biologic therapies in severe asthma

2. GINA Main Report.Global Initiative for Asthma ‐ GINA.2023https://ginasthma.org/2023‐gina‐main‐report/

3. Eosinophilic inflammation: an appealing target for pharmacologic treatments in severe asthma;Vatrella A;Biomedicine,2022

4. Interleukins 4 and 13 in Asthma: Key Pathophysiologic Cytokines and Druggable Molecular Targets

5. Mepolizumab decreases tissue eosinophils while increasing type‐2 cytokines in eosinophilic chronic rhinosinusitis

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Benralizumab reduces blood basophil percentage and activation in vitro without eliciting degranulation;Allergy;2024-06-06

2. Correction to “Long‐term immune response accompanies clinical outcomes in severe asthmatics treated with anti‐IL‐5/IL‐5R biologics”;Allergy;2024-03-12

3. Sputum cytokines associated with raised FeNO after anti‐IL5 biologic therapy in severe asthma;Allergy;2024-01-10

4. Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients;Archivos de Bronconeumología;2024-01